Go Deep
Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,871 | -1.1 | 0.73 | 0.00 | 313.51 |
| Oct 2026 | 22,875 | -1.1 | 0.73 | 0.00 | 312.56 |
| Oct 2026 | 21,071 | -1.1 | 0.73 | 0.00 | 313.84 |
| Oct 2026 | 20,017 | -1.1 | 0.75 | 0.00 | 321.43 |
| Oct 2026 | 19,954 | -1.1 | 0.77 | 0.00 | 329.15 |
| Oct 2026 | 19,954 | -1.1 | 0.77 | 0.00 | 328.48 |
Neuphoria Therapeutics Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,174,165.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -4,904,456.0 | -505,063.0 | 1,864,092.0 | -9,906,504.0 |
| EPS | — | -0.1 | 0.4 | -4.4 |
Neuphoria Therapeutics Inc. Revenue & Profit: Last 5 Years
| Line Item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
| Revenue | 1,174,165.0 | — | 0.0 | 0.0 | 181,356.3 |
| Net Profit | -13,451,931.0 | — | -15,492,166.0 | -21,381,677.0 | -14,968,464.9 |
| EPS | — | -0.2 | -18.6 | -0.2 | -0.2 |
Neuphoria Therapeutics Inc. Balance Sheet
| Line Item | Jun 2026 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|
| Total Assets | 28,709,016.0 | 27,649,093.0 | 28,562,948.0 | 44,927,475.1 |
| Total Liabilities | 4,108,994.0 | 10,158,721.0 | 6,552,385.0 | 5,776,593.2 |
| Total Equity | 24,600,022.0 | 17,490,372.0 | 22,010,563.0 | 39,150,881.9 |
Owes vs Owns
Neuphoria Therapeutics Inc. owed $0.14 for every $1 it owned in Jun 2026, up from $0.13 in Jun 2022.
| Period | Jun 2026 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|
| Owes vs Owns | 0.14× | 0.37× | 0.23× | 0.13× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Neuphoria Therapeutics Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Jun 2026
Cash & short-term investments 69.2%Receivables 2.8%Intangible assets 26.6%Other assets 1.4%
How it's funded — Jun 2026
Payables 1.3%Other liabilities 12.8%Shareholders' equity 85.7%
| Line Item | Jun 2026 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 19.9 | 12.6 | 12.1 | 23.1 |
| Receivables | 0.8 | 0.1 | 0.4 | 4.7 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 0.2 | 0.3 | 0.5 |
| Intangible assets | 7.6 | 14.2 | 14.8 | 15.6 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 0.4 | 0.5 | 0.9 | 1.1 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.1 |
| Long-term debt | 0.0 | 0.1 | 0.2 | 0.4 |
| Payables | 0.4 | 2.2 | 1.4 | 1.1 |
| Other liabilities | 3.7 | 7.8 | 4.8 | 4.2 |
| Shareholders' equity | 24.6 | 17.5 | 22.0 | 39.2 |
| Net tangible assets | 17.0 | 3.3 | 7.2 | 23.5 |
Neuphoria Therapeutics Inc. Cash Flow
| Line Item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
| Operating Activities | -12,353,074.0 | — | -14,680,777.0 | -14,637,720.0 | -14,965,802.0 |
| Investing Activities | — | — | — | 317,414.8 | 427,675.3 |
| Financing Activities | 17,915,883.0 | — | 15,108,794.0 | 3,858,451.0 | 18,570,539.6 |